10.05.2013 - Cardio3 BioSciences has increased its equity by €19m through a private placement of existing investors.
The new funds will be used to finance further clinical development of C3BS-CQR-1 (C-Cure®) in the CHART-1 study (Congestive Heart failure Cardiopoietic Regenerative Therapy), said the company. Recently, Cardio3 BioSciences (Mont-Saint-Guibert) published proof-of-concept data of a Phase II trial of its autologous stem cell therapy for chronic heart failure following ischemic cardiomyopathy. The Belgian company reprogrammes autologous bone marrow cells into ‘cardiopoïetic’ cells with the aim of growing new heart tissue thereby repairing damaged heart muscle. The therapy was licenced from researchers at the Mayo Clinic (Rochester, Minnesota, USA).
Of the €19m raised, €7m is in new equity committed by existing investors, with €12m resulting from the conversion of existing convertible loans. The formal capital increase was approved at a shareholder meeting and is expected to complete by the end of May 2013.
Christian Homsy, CEO of Cardio3 BioSciences, said: „The new funding will allow us to proceed with our European Phase III trial in patients with Congestive Heart failure. We are confident that this study will confirm that C-Cure has the potential to significantly improve the disease course of those very sick patients, and could lead to a paradigm shift in the treatment of heart failure.“
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.
06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.